Congresses

Title Yearsort descending
The D2AMR group: Discovery and development of Antimicrobials and Mechanisms of drug Resistance 2017
Innovative drug discovery and development strategies for antibacterial therapy: a focus on neglected diseases  2017
Discovery of new therapies for Buruli ulcer treatment 2017
Repurposing clinically approved cephalosporins for tuberculosis therapy 2017
Sesión II: Antimicrobianos (Moderador) 2018
Estudios iniciales para la caracterización del modo de acción molecular de las avermectinas como agentes anti-tuberculosos 2018
Towards the elucidation of rifampicin/betalactam synergistic interactions against M. tuberculosis 2018
Discovery and Development of Antimicrobials and Mechanisms of Drug Resistance 2018
Development of a high-throughput method for synergistic drug combinations screening 2018
Repurposing beta-lactams for buruli ulcer treatment 2018
REPURPOSING BETA-LACTAMS FOR BURULI ULCER TREATMENT 2018
Preliminary studies to elucidate the mode of action of a new chemical series with antimicrobial activity 2018
Discovery and Development of Antimicrobials and Mechanisms of Drug Resistance 2018
ANTHELMINTIC AVERMECTINS FOR THE TREATMENT OF NON-TUBERCULOUS MYCOBACTERIA INFECTIONS IN CYSTIC FIBROSIS 2018
Anthelmintic avermectins for the treatment of non-tuberculous mycobacteria infections in cystic fibrosis 2018
Caracterización biológica de una nueva serie de compuestos químicos con actividad antimicrobiana 2018
Towards efficient in vitro screening tools to discover new clinical options in the treatment of non-tuberculous Mycobacteria 2019
PRELIMINARY STUDIES FOR THE ELUCIDATION OF THE MODE OF ACTION OF THE AVERMECTINS AS ANTI-TB AGENTS 2019
Towards the elucidation of the rifampicin/beta-lactam synergy in mycobacteria 2019
In vitro profiling of anthelmintic avermectins against non-tuberculous mycobacteria 2019

Pages